Natriumoksibaatti Kalceks (Sodium Oxybate)

Sodium oxybate acts as an agonist at GABA_B receptors in the central nervous system. By enhancing inhibitory signaling, it increases slow‑wave sleep, stabilizes sleep architecture, and diminishes the sudden loss of muscle tone that characterises cataplexy.

The exact dose of sodium oxybate is individualized and set by the prescribing clinician. Dosing typically starts at a low level and is titrated based on therapeutic response and tolerability, following local regulatory guidelines.

Safety data for sodium oxybate in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike wake‑promoting agents such as modafinil, sodium oxybate is taken at night and primarily improves nocturnal sleep and cataplexy. It addresses both sleep fragmentation and muscle‑tone loss, whereas other agents mainly target daytime alertness without directly reducing cataplexy.

The oral solution should be stored at ambient temperature, below 25 °C, in its original container. Keep it away from moisture, direct sunlight, and extreme heat to maintain stability and potency.

It is supplied as an oral solution that is measured with a calibrated device and taken at night, usually two doses separated by 2.5 to 4 hours. The medication must be swallowed, not injected, and patients should follow the prescriber’s timing instructions.

The most critical safety concerns include respiratory depression, severe hypotension, seizures, and potential for abuse or dependence. Patients should be monitored closely for any signs of breathing difficulty, sudden drops in blood pressure, or unusual behavioral changes.

Sodium oxybate is contraindicated in individuals with severe respiratory disorders, known hypersensitivity to the drug, or those who are currently abusing alcohol or other CNS depressants. It should also be avoided in patients for whom the risk‑benefit profile is unfavorable, as determined by a qualified healthcare professional.